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Abstract
Background: A major unresolved safety concern for malaria case management is the use of artemisinin
combination therapies (ACTs) in the first trimester of pregnancy. There is a need for human data to inform policy
makers and treatment guidelines on the safety of artemisinin combination therapies (ACT) when used during early
pregnancy.
Methods: The overall goal of this paper is to describe the methods and implementation of a study aimed at
developing surveillance systems for identifying exposures to antimalarials during early pregnancy and for
monitoring pregnancy outcomes using health and demographic surveillance platforms.
This was a multi-center prospective observational cohort study involving women at health and demographic
surveillance sites in three countries in Africa: Burkina Faso, Kenya and Mozambique [(ClinicalTrials.gov Identifier:
NCT01232530)]. The study was designed to identify pregnant women with artemisinin exposure in the first
trimester and compare them to: 1) pregnant women without malaria, 2) pregnant women treated for malaria, but
exposed to other antimalarials, and 3) pregnant women with malaria and treated with artemisinins in the 2nd or
3rd trimesters from the same settings. Pregnant women were recruited through community-based surveys and
attendance at health facilities, including antenatal care clinics and followed until delivery. Data from the three sites
will be pooled for analysis at the end of the study. Results are forthcoming.
Discussion: Despite few limitations, the methods described here are relevant to the development of sustainable
pharmacovigilance systems for drugs used by pregnant women in the tropics using health and demographic
surveillance sites to prospectively ascertain drug safety in early pregnancy.
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Background
Artemisinin-based combination therapies (ACTs) are
among the most rapidly acting and effective antimalar-
ials, providing life-saving benefits to adults and children.
Almost all malaria-endemic countries have adopted
ACTs as the first-line treatment for P. falciparum [1].
ACTs are recommended for the treatment of malaria
during the second and third trimesters of pregnancy.
However, artemisinin compounds are not recommended
for use in the first trimester of pregnancy, unless there
are no other drugs available, due to concerns about their
potential embryolethal and teratogenic effects. With ex-
panded access to ACTs, a growing number of women
will likely be inadvertently exposed to an ACT in early
pregnancy, during the period of organogenesis [2, 3].
While ACTs are not recommended for use during early
pregnancy, pregnant women need safe and effective
treatment and prevention measures to avoid the sub-
stantial adverse consequences of malarial infections to
themselves and their developing fetuses. Adverse conse-
quences of untreated malaria in pregnancy include se-
vere anemia for women and low birth weight (LBW) for
newborns, one of the principal causes of infant mortality
in the African region [4]. Any risk of exposure to ACTs
in early pregnancy must therefore be carefully weighed
against the potential benefits of antimalarial treatment.
Animal reproductive toxicology studies of artemisinins
demonstrate that embryotoxicity occurs through inhibit-
ing human erythroid cell differentiation [5, 6], leading to
either embryolethality [7] or other significant dysfunc-
tion in embryo hematopoiesis [8]. Extrapolation of this
data to humans suggests that the embryo-sensitive
period may be between 4 and 10 weeks post-conception
[9], the period when the nucleated, metabolically active
primitive erythroblasts predominate in the blood. How-
ever, among humans, the period of embryo-sensitivity is
unclear, as the primitive erythroblasts are gradually
replaced over several weeks by enucleated mature eryth-
rocytes, which are less sensitive to the effects of artemi-
sinins. In more recently conducted animal studies, no
increase in toxicity was observed with the use of two ar-
temisinin drugs or artemisinins plus other antimalarials
[10, 11]. The limited safety data available from human
observational studies of artemisinins is reassuring with
no adverse effects on infants at birth or through their
first birthday reported to-date [12–19]. While embryo-
toxic effects have yet to be observed in epidemiologic
studies in humans, increased obstetric complications in-
cluding fetal distress at birth, Caesarean section births
and any adverse pregnancy outcome were observed in
one study among women treated with artemisinins in
pregnancy, specifically among primigravidae and older
women [20]. Therefore, improvement of surveillance
methodologies and ongoing assessment of the safety of
ACTs in pregnancy remains important for malaria-
endemic settings.
There have been multiple calls for generating more
safety data on use of the artemisinins in early pregnancy
in humans and for new approaches to obtain more sys-
tematically collected safety information during the post-
marketing phase http://www.who.int/malaria/publica-
tions/atoz/9789241596114/en/. Pregnant women are
routinely excluded from pre-licensure clinical trials for
fear of harming the mother or the developing fetus, and
thus most medicines, including ACTs, are marketed with
very limited information on safety or efficacy during
pregnancy. Although the World Health Organization
(WHO) does not recommend the use of ACTs in the
first trimester unless there is no alternative and the life
of the woman is in danger, reports of antimalarial drug
use among pregnant women in some settings show fre-
quent use of ACTs [20–22]. This situation, medicines
not recommended therefore not prescribed—not pre-
scribed therefore no information, has rightly been de-
scribed earlier as a “Catch-22” [23]. We previously
estimated that with an average of 32 million pregnancies
occurring annually in malaria endemic countries in Af-
rica, an estimated 1 to 2 million pregnancies are exposed
to ACTs during the embryo-sensitive period [24]. With-
out prescribing indications (except 2nd and 3rd trimes-
ter) or risk management programs for women of
childbearing age (WOCBA) or women with suspected or
confirmed pregnancy, the potential for inadvertent ex-
posure to artemisinins during early pregnancy is high,
and in many cases, unavoidable.
As part of a robust and sustainable approach to mal-
aria case management, safe and effective antimalarial
treatments must be identified for women during early
pregnancy. Pharmacovigilance is needed to detect, re-
port, and manage possible adverse effects of artemisinins
on pregnancy outcomes. Improved methods for pharma-
covigilance in early pregnancy are needed to inform the
development of treatment guidelines and evidence-based
practices. Herein, we describe a novel observational
methodology using active surveillance techniques for
pharmacovigilance of antimalarial use in early preg-
nancy, with an emphasis on assessing the effects of
exposure to ACTs within health and demographic sur-
veillance sites. This approach has been field-tested in
three sites associated with the Malaria in Pregnancy
Consortium (MiPc). Herein we provide an overview of
the methods. The study results will be presented separ-
ately following completion of the study and data
analysis.
Goal and study aims
The goal of the Assessment of the Safety of Antimalarial
Drug Use During Pregnancy (ASAP) study was to
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develop surveillance systems for identifying exposures to
antimalarials during early pregnancy and for monitoring
pregnancy outcomes. The specific aims were to develop
and field-test active surveillance tools and procedures
for identifying ACT exposure in early pregnancy and for
assessing pregnancy outcomes, including assessment of
major congenital malformations detected by a surface
examination, miscarriages, stillbirths and live births. A
further aim was to contribute data to inform the
evidence-base and safety profile regarding the relation-
ship between use of ACTs during early pregnancy and
risk of adverse pregnancy outcomes such as miscar-
riages, stillbirths, and major congenital malformations.
The protocol was reviewed and approved by the Ethical
Review Boards of the Kenya Medical Research Institute
(KEMRI), U.S. Centers for Disease Control and Prevention
(CDC), National Bioethics Committee in Mozambique,
Centre Muraz Institutional Ethics committee and National
Ethics committee in Burkina Faso, Liverpool School of
Tropical Medicine in the UK, and the Institutional Review
Board of the University of Washington.
Methods
Study design
This multi-centered, non-interventional, prospective co-
hort study consisted of field activities at three MiPc
partner sites in sub-Saharan Africa located in Siaya
County, Kenya; Nanoro, Burkina Faso; and Manhiça,
Mozambique. All sites were involved in developing and
field-testing active surveillance methods for identifying
exposures to antimalarials during early pregnancy; moni-
toring pregnancy outcomes; and assessing infant out-
comes. Guided by a common protocol, each site
implemented prospective observational methodologies
within their operating health demographic surveillance
system (HDSS) programs, allowing for active surveil-
lance and records linkage for ACT exposures and preg-
nancy outcomes, with an emphasis on identifying first-
trimester exposures to antimalarials. Moreover, all sites
identified and recruited women as early as possible in
pregnancy.
Study sites
All three study sites are under health and demographic
surveillance system (HDSS) and members of the Inter-
national Network of field sites with continuous Demo-
graphic Evaluation of Populations and Their Health in
developing countries (INDEPTH) [http://www.indepth-
network.org/]. Through the HDSS, vital events such as
pregnancies, births, migrations and deaths are moni-
tored, and information on household and socio eco-
nomic characteristics are collected through household
visits carried out on regular basis. The HDSS provides a
platform to identify women of childbearing age and
pregnancies as well as to follow them through active sur-
veillance of pregnancy outcomes.
Asembo - Siaya County, Kenya
Siaya is a rural community located in Rarieda District in
Siaya County, lying northeast of Lake Victoria in Nyanza
Province, western Kenya. The site is part of the KEMRI/
CDC Research and Public Health Collaboration HDSS
which has been described in detail elsewhere. In this
area, P. falciparum malaria transmission is perennial and
holo-endemic with approximately 18 % of pregnant
women being parasitemic at first antenatal clinic visit
[25, 26]. The selected study area covered 33 villages and
approximately 25,000 people under HDSS and enhanced
morbidity surveillance since 2005 through the KEMRI/
CDC International Emerging Infection Program (IEIP)
to investigate major infectious disease syndromes [27].
As part of this population-based infectious disease sur-
veillance project (PBIDS), trained fieldworkers visited
households regularly (on a weekly basis from January 5,
2010 to May 26, 2011 and then bi-weekly from May 27,
2011 onwards) collecting information on all symptoms
since the previous visit, the source of care and any medi-
cation taken, including specific antimalarial medication.
All PBIDS participants receive free care for infectious
symptoms at a referral health facility, Lwak Mission
Hospital, where information on diagnosis and treatment
is recorded using the HDSS ID for record linkage. The
study was carried out in collaboration with PBIDS to en-
abling cross-validation of drug exposure data obtained
through prospective home visits, health facility records
and self-report during pregnancy.
Nanoro, Burkina Faso
The Nanoro Department is located in central Burkina Faso,
West Africa, approximately 85 Km from Ouagadougou, the
capital city. The study area is located within the HDSS
catchment area and covers approximately 33,300 people liv-
ing in 15 villages. Malaria is hyperendemic with seasonal
transmission (July–November). It represents the main rea-
son for consultations at health facilities all year round, with
a peak between September and November. The disease
represents a significant burden on the population, but espe-
cially pregnant women and children. Plasmodium falcip-
arum is the main malaria species. The Nanoro HDSS was
established in 2009 by the Clinical Research Unit of Nanoro
(CRUN). It covers a size of 600 Km2 for a total population
of 63,000 inhabitants in 24 villages (8 peripheral health fa-
cilities) [28]. In addition to the regular surveys, a continu-
ous weekly monitoring is conducted by village reporters.
The CRUN is located in the Centre Médicale Saint Camille
de Nanoro (CMA), the referral hospital of the Nanoro
health district [29]. A fully functioning clinical laboratory
(parasitology, biochemistry, hematology, microbiology and
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blood/cells in vitro culture) and digital X-ray facility, have
been set up with new equipment (all validated before their
first use), including back-up equipment to ensure reliable
services. Therefore most routine diagnosis for patients care
management can be done locally on site.
Manhiça, Mozambique
The Manhiça District is a rural community located in
southern Mozambique, 80 km north of Maputo city.
The site is part of the Centro de Investigação em Saúde
de Manhiça which collaborates with Eduardo Mondlane
University, Mozambique, and the Centre for Inter-
national Health, University of Barcelona, Spain. This site
is well described elsewhere [30]. P. falciparum malaria is
the most prevalent in the site and transmission is peren-
nial with two well-demarked seasons, a dry season
(May-October) and a rainy season (November-April).
The entomological inoculation rate estimated in 2002
was of 38 infective bites/person/year [31]. In addition to
the HDSS of approximately 92,000 inhabitants, the cen-
ter has a morbidity platform to monitor information on
illnesses and treatments for individuals under 15 years
old through registries of all outpatient and inpatient
visits to the health facilities in the HDSS area. This plat-
form includes all five peripheral health facilities and the
referral Manhiça District Hospital. The clinicians work-
ing on this platform are trained on malaria diagnosis
and case management and to record all visit including
information on diagnose, laboratory results and treat-
ments prescribed. A basic laboratory facility is available
for blood smear and hemoglobin (using Hemocue). A
standardized form is used for outpatient and inpatient,
data is recorded in a database and available for record
linkage. As part of this study, the morbidity platform
was extended to include women in childbearing age
(15–49 years).
Training
Training was critical to support high quality data and
standardization across sites. In addition to the overall
protocol and ethics training, nurses from all sites were
trained on newborn examination for recognition of con-
genital malformations. They were also trained in the use
of Ballard score as well as ultrasound for gestational age
assessment. The nurses were informed that the purpose
of the newborn examination was to identify certain
problems the baby may have been born with, and there-
fore provide each baby with the best appropriate care
available; and to document the occurrence of congenital
malformations, or birth defects, in each country, which
can help in understanding the safety of medications
given during pregnancy. Participants were also urged
that the success of the project depended on the quality
of the examiner’s work and that having a routine order
of examination makes it less likely to forget any parts of
the examination. The ultrasound training was targeted
to the nurses from the antenatal clinic and focused on
pregnancy identification, assessment of fetal vitality and
gestational age calculation. For pregnancy identification,
the trainees had to identify gestational sacs, embryos or
heart beats and for gestational age assessment they were
trained on measurement of crown‐rump length, biparie-
tal diameter, head and abdominal circumference and
femur length using standard training manuals developed
by the Malaria in Pregnancy Consortium (see Additional
file 1 and Additional file 2).
Community sensitization
Our first step involved community sensitization through
meetings held at each location with community leaders
aiming at informing them about the planned study and
providing a forum for questions and clarification. This
was an important step to ensure good participation, par-
ticularly when addressing potentially sensitive subjects
such as pregnancy in Africa. Indeed previous studies on
malaria in pregnancy have highlighted the importance of
the social context for the uptake of interventions [32].
Therefore researchers should take into account the cul-
tural and ethical norms of the population(s) under study.
Sensitization of the community for early detection of
pregnancies and early presentation at ANC was con-
ducted by social scientists. Pregnant women were also
informed about the availability of pregnancy tests and
ultrasound for pregnancy diagnosis at ANC. Printed in-
formative material was distributed through community
meetings.
Enrollment into the study
Guided by an overall study protocol, the three individual
field sites developed novel enrollment and registry prac-
tices to create infrastructure for surveillance of medica-
tions used in pregnancy. Eligible participants consisted
of pregnant women residing in the defined catchment
areas of each site, who planned to remain in the study
area through delivery and who were willing and able to
provide written informed consent. Exclusion criteria
across all study sites were refusal to participate or be
followed up at the end of pregnancy and any condition
that would interfere with the ability to provide written
informed consent or provide an accurate medical his-
tory. In Mozambique and Burkina Faso, pregnant
women were identified within the health demographic
surveillance system (HDSS) through repeated surveys as
described above. In addition, field workers visited village
reporters on weekly basis to learn about any pregnancy
identified in their community. All identified pregnant
women were invited to the ANC and assessed for eligi-
bility. Baseline information was then collected and the
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data entered into a pregnancy register. Records linkage
with data collected at outpatient and inpatient visits
using electronic data capture method was also used in
the two sites for identify possible exposure to ACTs dur-
ing the first trimester of the pregnancy. In Kenya, re-
cruitment was broadened to include women of
childbearing age participating in the PIBDS program de-
scribed above in order to detect pregnancies as early as
possible through community based strategies. Study staff
visited all homes in the PBIDS and enrolled consenting
women of childbearing age who were assessed for preg-
nancy at the time of enrolment and again approximately
every 3 months thereafter. Any participant with a de-
tected pregnancy was referred to the antenatal clinic at a
study health facility where trained study nurses would
confirm the pregnancy and offer free ANC. Additionally,
all eligible, consenting women in ANC at the study facil-
ity were assessed and enrolled.
At enrollment, each site collected detailed demo-
graphic data, information on possible risk factors and
potential confounders via a detailed questionnaire ad-
ministered to enrolled participants at first ANC visit,
any antenatal follow up visit and at the end of
pregnancy. Table 1 presents the sources of information
for drug exposure and pregnancy outcomes by study
site. Demographic and socioeconomic data, history of
malaria episodes, co-morbidities, other medication use
(including herbal or traditional remedies) during preg-
nancy, and obstetric history were collected from all
participants.
Ascertainment of antimalarial drug exposures
The ascertainment of drug exposure was multi-modal
and included self-report (prospective and retrospective)
and linkage to treatment records at local health facilities,
drug prescribing and dispensing clinics. The following
definitions were used to classify “possible” ACT expos-
ure as exposure identified in only one data source and
“confirmed” ACT exposure as exposures identified in 2+
data sources (for example self-report during interview at
ANC visit and confirmed in health facility outpatient
records).
Drug identification Before study initiation an assess-
ment of antimalarials available in the study areas was
conducted and country-specific visual aids and pictorial
keys were prepared. These tools were used to assist the
participants recall drug names during interviews. Study
staff reviewed participants’ drug packages or tablets
when available, as well as reviewed and abstracted pre-
scribing information from ANC cards, where available.
Data collected included timing of exposure, medication
name, dose, and duration.
Retrospective self-reported drug exposure Subjects
were asked about exposure to antimalarials and other
medications currently used and used earlier in their
pregnancy at a baseline interview conducted by study
staff. Subjects were also asked about exposures at an
ANC clinic visit after pregnancy status was confirmed as
well as at all ANC visit and during pregnancy outcome
follow-up visits. The timing of possible drug exposures
and possible peri-conceptional exposure was dated
retrospectively using estimated gestational age. Medica-
tion use that was self-reported to have been prescribed
or dispensed at the health facility was verified and
matched with drug prescription records at health care
facilities, clinic databases of drug prescribing and dis-
pensing, ANC clinic visit records, and records from de-
livery units where possible.
Health facility records drug exposures Records on
drugs dispensed at health facilities located within the
study catchment areas were extracted from the health
facility log-books, from the morbidity surveillance data-
base and/or systematically abstracted from outpatient
department records.
Prospective self-report drug exposures The PBIDS
program in Kenya offered a unique opportunity to col-
lect prospective detailed data on drug exposure and
morbidity on a weekly and then bi-weekly basis at home,
which limits recall bias and potentially improves specifi-
city in reports of the timing of drug exposure.
Table 1 Summary of ascertainment of drug use approaches by study site
Event Source Sites
Asembo Manhiça Nanoro
Drug exposure Retrospective Self-report √ √ √
Health Facility Treatment records √ √ √
Outpatient visit database √
Prospective Self-report √
Pregnancy outcomes Health facility assessment √ √ √
Home base assessment √ √
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Gestational age assessment and classification
The accurate assessment of gestational age was essential
to identify drug exposures occurring during the embryo-
sensitive period and avoid misclassification of exposure.
Gestational age was assessed via multiple methods, as
available, including date of last menstrual period, Ballard
Score, fundal height and ultrasound (Table 2). Study staff
were trained on newborn examination for Ballard Score
assessment as well as fundal height measurement. They
were also trained on the use of ultrasound dating scans
using portable ultrasound machines, i.e., Sonosite 180
plus, Sonosite Inc. USA. Women were encouraged to at-
tend ANC as early as possible where free ultrasound
scans were offered to participants presenting before
24 weeks of gestation [33, 34]. The study nurses were
trained on identification of the pregnancy, assessment of
gestational age and to refer any suspicion of abnormality
for better assessment to a physician. Quality control for
ultrasound scans was implemented following the ultra-
sound training of the study nurses. All ultrasound im-
ages were downloaded from the machine to a laptop and
a random sub-sample (20 %) were sent after removing
all identifiers from the images to a consulting ultrasound
radiologist located at the University of Washington. This
reviewer provided feedback to the midwives highlighting
areas needing re-training or special attention. If re-
quired, additional training materials were sent for review
with the study nurses. Additionally, fundal height was
also measured at each ANC visit at the study health fa-
cilities and recorded by a trained study nurse and infor-
mation on last menstrual period was collected. Ballard
score was performed and dated by trained health care
providers at all sites within 7 days of birth.
Pregnancy outcomes assessment
Pregnancy outcomes of interest consisted of miscar-
riages, elective terminations, fetal deaths/stillbirths, low
birthweight, small for gestational age, and live births.
Fetal resorption and spontaneous abortion were clear
safety signals from pre-clinical studies in all species
studied and miscarriage was therefore an important end-
point to consider for the risk-benefit evaluation of ACTs.
All participants were encouraged by study staff to deliver
at the nearest health facility, and both health facility-
based and home-based follow-up systems were used to
ascertain pregnancy outcomes, as home birth remained
common in all three sites. For home-based follow-up,
traditional birth attendants (TBAs) were instructed to
alert study staff of the occurrence of any pregnancy out-
come, including miscarriage, stillbirth or live birth. Fol-
lowing a home delivery, study staff visited the household
as soon as possible [48 h in Burkina Faso, up to the
6 weeks postnatal appointment (post-partum visit) in
Mozambique and no cut off were specified in Kenya]
following the event to administer a standard question-
naire and examine the newborn (including live births
and stillbirths where possible). Study staff were blinded
to the exposure status of women, and trained to system-
atically collect pregnancy outcomes and conduct
newborn examinations using a “newborn surface exam-
ination manual” produced by MiPc. All information col-
lected including vital status of the baby, sex, head
circumference, length and weight was recorded on a
pregnancy outcome case report form (CRF). The date,
place and time of examination, and the age of the baby
at examination (number of days since birth) were also
collected, so that analysis can separate babies assessed at
birth from those assessed some time later. Any abnor-
malities observed and any adverse outcomes in the
mother or baby were noted and reported in the CRF.
A systematic surface examination based on the MiPc
standard manual (see Additional file 1) was carried out
to identify congenital anomalies which are visible to the
examiner and do not require specialized staff or equip-
ment. Digital photographs of abnormalities were taken
for the purposes of confirmation and classification.
Cases of suspected malformation or abnormality were
reviewed by a study pediatrician for confirmation. Cases
needing further investigation or intervention were re-
ferred to the appropriate facilities/ specialist.
Table 2 Accuracy of gestational age assessment by method
Method of Gestational Age Assessment Accuracy Correctiona,b,c Accuracy Scaled
Ultrasound before 14 gestational weeks ±5 days 1 (most accurate)
Ultrasound between 14 and 28 gestational weeks ±2 weeks 2
Ultrasound after 28 gestational weeks ±3 weeks 3
Ballard score within 7 days of birth ±2 week 4
LMP ±4 weeks 5
Fundal Height ±6 weeks 6 (least accurate)
a[37]
b[38]
c[39]
dGestational age was be assessed using the most accurate technique available
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Sample size determination
The required sample size was determined using the
minimum relative risk (RR) to be detected and the fre-
quency of adverse pregnancy outcomes of interest in the
non-exposed or comparison population. A summary of
number of exposed and unexposed pregnancies to be re-
cruited per site are provided in the Table 3.
The ratio of exposure to antimalarials versus non-
exposure in early pregnancy was estimated to be ap-
proximately 1:16 in Mozambique and Burkina Faso and
1:30 in Kenya where the probability of inadvertent ex-
posure would be reduced significantly due the introduc-
tion of pregnancy testing at the household level. This
was based on a number of assumptions, as follows: 1)
the average pregnancy is 266 days (38 weeks) from con-
ception (280 days or 40 weeks from LMP), 2) the aver-
age number of treatments with ACTs in adults in the
study areas is approximately 0.5 treatments per year (1
every 2 years), and 3) the total fertility rate is estimated
at 5.5 [30]. Under these conditions, we estimated the
probability that an embryo would encounter artemisi-
nins inadvertently during the critical 42 day (6 weeks)
period of its development (week 4 to week 9 inclusive,
from conception) is about 6.0 %. In the absence of regu-
lar pregnancy testing to exclude early pregnancy, the po-
tential ratio of exposed versus unexposed pregnant
women is estimated at 1:16. However, in Kenya, we an-
ticipated that the probability of inadvertent exposure
would be reduced significantly, to approximately 3.0 %,
as pregnancy would likely be detected earlier and there-
fore less inadvertent exposure would result. We there-
fore expected the ratio of exposed to unexposed in
Kenya to be approximately 1:32.
Miscarriages
A conservative estimate is that only 50 % of the pregnan-
cies will provide sufficient information to contribute to
the analysis due to refusal to participate, late recruitment,
loss to follow-up, uncertainties about gestational age as-
sessment or unreliable data on drug exposure. The back-
ground rate of clinically recognized miscarriages (from 6
to 28 weeks post-LMP) is estimated at 12.2 %. There are
no published data on background rates of miscarriage for
the study area or overall for Kenya, however, it is likely
that a significant proportion of early miscarriages could be
missed (especially between 6 to 9 weeks gestation). If one
assumes that only two-thirds of the miscarriages can be
captured (8.1 %), a sample size of 466 documented preg-
nancies (14 exposed and 452 unexposed women) was
calculated to have 80 % power to exclude a 3.1 fold in-
creased risk of spontaneous abortions from 8.1 % back-
ground rate to 25.2 % in exposed pregnancies (1-sided
alpha level of 0.05).
Congenital malformations
Because information on background rates of major mal-
formations is not available for Africa, the background
rate in the unexposed control group was based on esti-
mates from the USA [35, 36]. The anticipated back-
ground rate of major malformation detectable at birth is
approximately 2 % in western populations (and 3 % by
5 years of age), but this estimate includes major malfor-
mations that are not easily detectable by non-specialized
staff (e.g., cardiac malformations). The rate of major
congenital malformations among 69,277 live-born and
stillborn infants and elective terminations at Brigham
and Women’s Hospital in Boston was 2.2 % at birth [36].
Of these, about 0.6 % due to chromosomal abnormalities
and genetic disorders, and the remaining 1.6 % were due
to non-genetic defects. Of the non-genetic defects, 0.7 %
was birth defects which are not easily detectable at birth
without specialized staff and equipment (such as heart
defects) [35]. Therefore, we restricted the assessment at
birth to visual inspection and a surface examination,
conservatively anticipating that the prevalence of major
malformations detectable at birth would be approximately
Table 3 Summary of number of exposed and unexposed pregnancies to be recruited per site
Sites Approximate
Population Size
Approximate
Pregnancies per year
Projected number of
exposures per yeara
Sample Size over 1 years of
recruitmentb
Ratio of exposed
to unexposed
Embryo sensitive period
6 weeks (exposure risk %)
Fully
documented
Exposed
Fully documented
Unexposed
Kenya 25,000 1085 3 % 14 458 1:30
Burkina Faso 30,000 1000 6 % 42 658 1:16
Mozambique 33,000 1000 6 % 42 658 1:16
Overall 88,000 3085 98 1768
aThis was based on a number of assumptions, as follows: 1) the average pregnancy is 266 days (38 weeks) from conception (280 days or 40 weeks from LMP), 2)
the average number of treatments with ACTs in adults in the study areas is approximately 0.5 treatments per year (1 every 2 years), and 3) the total fertility rate is
estimated at 5.5 [29]. Under these conditions, we estimated the probability that an embryo would encounter artemisinins inadvertently during the critical 42 day
(6 weeks) period of its development (week 4 to week 9 inclusive, from conception) is about 6.0 %. In the absence of regular pregnancy testing to exclude early
pregnancy, the potential ratio of exposed versus unexposed pregnant women is estimated at 1:16. Exposure risk will be lower for the Asembo site as some
women will be detected early and will be counselled not to take ACTs in the first 3 months of pregnancy
bEstimating that about 70 % of exposures can be documents reliably and followed up to pregnancy outcome
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0.9 %. Table 3 shows the sample size based on the es-
timated number of live-births and stillbirths in the 3
study sites if likelihood of ACT exposure was 6 % in
Burkina Faso and Mozambique, and a 3 % exposure
risk in western Kenya. All sites assume 0.5 treatments
with ACTs in an adult population and a fertility rate
of 5.5. A sample size of 3085 women was estimated
to contribute 1866 (70 %) documented pregnancies to
the analysis (98 exposed and 1768 unexposed) after
accounting for possible attrition (i.e., loss to follow
up, unreliable gestation or exposure data). With this
minimum estimated sample size, our study was 80 %
powered to detect up to a 5-fold increased risk for
‘any’ major congenital malformations with a one-sided
alpha level of 0.05.
Discussion
The goal of this study was to develop surveillance
systems for identifying exposures to antimalarials during
early pregnancy and for monitoring pregnancy out-
comes. Although the methods described herein could
contribute to provide estimates of reassurance about the
safety profile of ACTs in early pregnancy, it presents
several limitations: Indeed, only the Kenya site where an
active surveillance system was carried out will allow the
detection of early miscarriage as well as the early identi-
fication of pregnancy. However although the active sur-
veillance system is more adequate for such detection/
identification, it is unlikely that a national pharmacovigi-
lance center or program in Africa can easily implement
such methods in their policies’ routine practices as this
will require more resources that typically available with-
out external support. Moreover, once detected, the
methods does not allow an easy assessment of induced
abortions (illegal in many Africa countries unless the life
of the mother is at risk) which could have been misclas-
sified as miscarriage or be loss to follow up. However in-
duced abortions are unlikely to differ between exposure
groups and therefore bias effect estimates. As another
limitation, the methods described here do not allow the
differentiation between confirmed and unconfirmed
malaria. This is particularly important in Africa where a
high percentage of women might be exposed to malaria.
In such context, it appears difficult to know the ‘’true
control group” without knowing the malaria infection
status of the non-ACT exposed pregnant women. Fi-
nally, the surface examination system used in this study
does not allow the detection of non-visual congenital ab-
normality such as heart defects.
Conclusion
Despite the few limitations listed above, this prospective
observational approach has the potential to contribute
additional data to inform the safety profile of ACTs in
early pregnancy, and inform the benefit-risk profile of
ACTs in similar populations. The optimal methodology
for drug safety surveillance in pregnancy in resource-
limited settings will likely vary based on local needs and
available resources; including available methods for
gestational age determination, possibility of community-
based pregnancy detection, assessment of pregnancy
outcomes, measurement of antimalarial exposure, and
confirmation of malaria cases. Our active surveillance
approach to pharmacovigilance in early pregnancy using
HDSS platforms can contribute tools for use or adapta-
tion in other settings, as well as serve as a resource to
inform the development of methods to identify signals
and evaluate potential risk from drug exposure in early
pregnancy.
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